S&P 500   5,258.09 (+0.18%)
DOW   39,811.48 (+0.13%)
QQQ   444.20 (-0.14%)
AAPL   171.75 (-0.90%)
MSFT   420.47 (-0.23%)
META   487.49 (-1.29%)
GOOGL   150.91 (+0.03%)
AMZN   180.16 (+0.18%)
TSLA   176.35 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.51 (-3.43%)
AMD   180.40 (+0.45%)
BABA   72.47 (+1.23%)
T   17.64 (+0.51%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   175.09 (-2.79%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.91 (+0.47%)
PYPL   67.13 (+0.84%)
XOM   116.06 (+0.95%)
S&P 500   5,258.09 (+0.18%)
DOW   39,811.48 (+0.13%)
QQQ   444.20 (-0.14%)
AAPL   171.75 (-0.90%)
MSFT   420.47 (-0.23%)
META   487.49 (-1.29%)
GOOGL   150.91 (+0.03%)
AMZN   180.16 (+0.18%)
TSLA   176.35 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.51 (-3.43%)
AMD   180.40 (+0.45%)
BABA   72.47 (+1.23%)
T   17.64 (+0.51%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   175.09 (-2.79%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.91 (+0.47%)
PYPL   67.13 (+0.84%)
XOM   116.06 (+0.95%)
S&P 500   5,258.09 (+0.18%)
DOW   39,811.48 (+0.13%)
QQQ   444.20 (-0.14%)
AAPL   171.75 (-0.90%)
MSFT   420.47 (-0.23%)
META   487.49 (-1.29%)
GOOGL   150.91 (+0.03%)
AMZN   180.16 (+0.18%)
TSLA   176.35 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.51 (-3.43%)
AMD   180.40 (+0.45%)
BABA   72.47 (+1.23%)
T   17.64 (+0.51%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   175.09 (-2.79%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.91 (+0.47%)
PYPL   67.13 (+0.84%)
XOM   116.06 (+0.95%)
S&P 500   5,258.09 (+0.18%)
DOW   39,811.48 (+0.13%)
QQQ   444.20 (-0.14%)
AAPL   171.75 (-0.90%)
MSFT   420.47 (-0.23%)
META   487.49 (-1.29%)
GOOGL   150.91 (+0.03%)
AMZN   180.16 (+0.18%)
TSLA   176.35 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.51 (-3.43%)
AMD   180.40 (+0.45%)
BABA   72.47 (+1.23%)
T   17.64 (+0.51%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   175.09 (-2.79%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.91 (+0.47%)
PYPL   67.13 (+0.84%)
XOM   116.06 (+0.95%)
NASDAQ:BGNE

BeiGene (BGNE) Stock Price, News & Analysis

$156.62
+1.54 (+0.99%)
(As of 02:39 PM ET)
Today's Range
$155.09
$157.38
50-Day Range
$141.80
$179.69
52-Week Range
$132.95
$272.49
Volume
57,204 shs
Average Volume
282,588 shs
Market Capitalization
$14.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$257.00

BeiGene MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
64.4% Upside
$257.00 Price Target
Short Interest
Healthy
1.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.52mentions of BeiGene in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$6.24 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.87) to ($2.31) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.82 out of 5 stars

Medical Sector

433rd out of 939 stocks

Pharmaceutical Preparations Industry

202nd out of 433 stocks

BGNE stock logo

About BeiGene Stock (NASDAQ:BGNE)

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

BGNE Stock Price History

BGNE Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
4 Analysts Assess BeiGene: What You Need To Know
BeiGene (NASDAQ:BGNE) Shares Gap Down to $163.70
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
BGNE Apr 2024 140.000 put
BGNE Apr 2024 220.000 call
BGNE Apr 2024 125.000 put
BGNE Apr 2024 180.000 call
BGNE Apr 2024 135.000 put
BeiGene Full Year 2023 Earnings: Beats Expectations
See More Headlines
Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BGNE
Fax
N/A
Employees
10,600
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$257.00
High Stock Price Target
$345.00
Low Stock Price Target
$161.00
Potential Upside/Downside
+65.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-881,710,000.00
Pretax Margin
-33.59%

Debt

Sales & Book Value

Annual Sales
$2.46 billion
Book Value
$37.10 per share

Miscellaneous

Free Float
88,504,000
Market Cap
$14.82 billion
Optionable
Optionable
Beta
0.62

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. John V. OylerMr. John V. Oyler (Age 56)
    Co-Founder, Executive Chairman & CEO
    Comp: $2.05M
  • Dr. Xiaobin Wu Ph.D. (Age 62)
    President & COO
    Comp: $1.69M
  • Dr. Xiaodong Wang Ph.D. (Age 61)
    Co- Chairman of Scientific Advisory Board & Non-Executive Director Co-Founder
    Comp: $250k
  • Ms. Julia Wang (Age 53)
    CFO & Principal Accounting Officer
    Comp: $964.2k
  • Mr. Wang Lai Ph.D. (Age 47)
    Global Head of R&D
    Comp: $996.92k
  • Ms. Liza Heapes
    Head of Investor Relations
  • Mr. Chan Lee
    General Counsel & Senior VP
  • Mr. Yang Ji
    Chief Compliance Officer
  • Dr. Yan Qi
    Senior VP & Head of Public Affairs - Greater China
  • Mr. Jason W. Radford (Age 42)
    Senior Vice President of Strategy & Corporate Development

Should I Buy BeiGene Stock? BGNE Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of BeiGene was last updated on Wednesday, March 27, 2024 at 11:41 PM.

Pros

Here are some ways that investors could benefit from investing in BeiGene, Ltd.:

  • BeiGene, Ltd. has a diverse portfolio of oncology medicines, including advanced treatments for various types of cancers such as blood cancers, solid tumors, and leukemia.
  • The company is actively developing a range of inhibitors and antibodies, indicating a strong pipeline for potential future growth and innovation in the oncology sector.
  • Collaborations with reputable companies like Amgen Inc., Novartis AG, and Bristol Myers Squibb company provide BeiGene, Ltd. with valuable resources, expertise, and opportunities for expansion.
  • Recent positive developments in the company's product offerings and partnerships have contributed to a positive market sentiment, potentially leading to increased stock value.
  • BeiGene, Ltd.'s focus on cutting-edge treatments and therapies aligns with the growing demand for advanced oncology solutions, positioning the company well in a competitive market.

Cons

Investors should be bearish about investing in BeiGene, Ltd. for these reasons:

  • Market volatility and regulatory challenges in the pharmaceutical industry can impact the company's performance and stock price, leading to potential investment risks.
  • Competition from other pharmaceutical companies and potential market saturation in certain therapeutic areas may pose challenges to BeiGene, Ltd.'s market share and revenue growth.
  • Dependency on successful clinical trials and regulatory approvals for new products could introduce uncertainties and delays in revenue generation, affecting investor confidence.
  • Fluctuations in global economic conditions and healthcare policies may influence the demand for oncology medicines, impacting BeiGene, Ltd.'s sales and profitability.
  • Investors should carefully consider the current stock price of BeiGene, Ltd. and evaluate whether it aligns with the company's financial performance, growth prospects, and market conditions before making investment decisions.

BGNE Stock Analysis - Frequently Asked Questions

Should I buy or sell BeiGene stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BGNE shares.
View BGNE analyst ratings
or view top-rated stocks.

What is BeiGene's stock price target for 2024?

9 analysts have issued twelve-month price targets for BeiGene's stock. Their BGNE share price targets range from $161.00 to $345.00. On average, they predict the company's stock price to reach $257.00 in the next year. This suggests a possible upside of 64.4% from the stock's current price.
View analysts price targets for BGNE
or view top-rated stocks among Wall Street analysts.

How have BGNE shares performed in 2024?

BeiGene's stock was trading at $180.36 at the beginning of the year. Since then, BGNE shares have decreased by 13.3% and is now trading at $156.34.
View the best growth stocks for 2024 here
.

Are investors shorting BeiGene?

BeiGene saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 1,730,000 shares, a decline of 10.4% from the February 29th total of 1,930,000 shares. Based on an average daily trading volume, of 294,100 shares, the days-to-cover ratio is presently 5.9 days.
View BeiGene's Short Interest
.

When is BeiGene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BGNE earnings forecast
.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) posted its quarterly earnings results on Monday, February, 26th. The company reported ($3.53) EPS for the quarter, topping the consensus estimate of ($3.61) by $0.08. The firm had revenue of $634.40 million for the quarter, compared to the consensus estimate of $632.52 million. BeiGene had a negative net margin of 35.86% and a negative trailing twelve-month return on equity of 23.12%. The company's quarterly revenue was up 66.9% compared to the same quarter last year. During the same period last year, the business posted ($4.29) EPS.

What is John V. Oyler's approval rating as BeiGene's CEO?

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

BeiGene (BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

Who are BeiGene's major shareholders?

BeiGene's stock is owned by many different retail and institutional investors. Top institutional shareholders include Capital International Investors (6.64%), Primecap Management Co. CA (5.23%), Baillie Gifford & Co. (4.05%), Price T Rowe Associates Inc. MD (2.00%), First Trust Advisors LP (0.23%) and Goldman Sachs Group Inc. (0.22%). Insiders that own company stock include Advisors Ltd Hhlr, Amgen Inc, Chan Henry Lee, Corazon (Corsee) D Sanders, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends
.

How do I buy shares of BeiGene?

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BGNE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners